Berzosertib and its Impurities

Berzosertib, also known as M6620, VX-970, or VE-822, is an investigational cancer drug and a first-in-class inhibitor of the ataxia telangiectasia and Rad3-related protein (ATR). As an investigational drug, berzosertib is being explored in clinical trials for its potential application in multiple cancer types. Reference standards of Berzosertib API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.